


TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/609,143
		Filing Date	June 27, 2003
		First Named Inventor	McLanague, Lisa C.
		Art Unit	1632
		Examiner Name	Crouch, D.
Total Number of Pages in This Submission	6	Attorney Docket Number	015270-012100US APR 05 2006

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form (1 p., submitted in duplicate). <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input checked="" type="checkbox"/> Terminal Disclaimer over 6,588,656, 6,245,964, 5,850,003, 5,612,486, and 5,604,102 (3 pp.). <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430. The attached Terminal Disclaimer, which disclaims U.S. Application No. 09/838,556 issued as U.S. Patent 6,588,656, U.S. Application No. 09/209,647 issued as U.S. Patent 6,245,964, U.S. Application No. 08/785,943 issued as U.S. Patent 5,850,003, U.S. Application No. 08/148,211 issued as U.S. Patent 5,612,486, U.S. Application No. 08/143,697 issued as U.S. Patent 5,604,102, are being filed simply as a precaution and should not be construed as an acquiescence to obviousness type double patenting.		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	Townsend and Townsend and Crew LLP	
Signature		
Printed name	Joe Liebeschuetz	
Date	April 5, 2006	Reg. No. 37,605

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Fax No. 1-571-273-8300, on April 5, 2005.			
Signature			
Typed or printed name	Yvonne Mock		Date April 5, 2006

60741635 v1

<i>Fee pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).</i>		RECEIVED CENTRAL FAX CENTER	
Fee Transmittal For FY 2006		APR 05 2006	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Filing Date June 27, 2003 First Named Inventor McLonlogue, Lisa C. Examiner Name Crouch, D. Art Unit 1632 Attorney Docket No. 015270-012100US	
TOTAL AMOUNT OF PAYMENT (\$ 130)			

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order None Other (please identify): _____
 Deposit Account Deposit Account Number: 20-1430 Deposit Account Name: Townsend and Townsend and Crew LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee
 Charge any additional fee(s) or underpayments of fee(s) Credit any overpayments
 under 37 CFR 1.16 and 1.17

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION (All the fees below are due upon filing or may be subject to a surcharge.)**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

<u>Application Type</u>	<u>FILING FEES</u>		<u>SEARCH FEES</u>		<u>EXAMINATION FEES</u>		<u>Fees Paid (\$)</u>
	<u>Small Entity</u>	<u>Fee (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEESFee Description

Each claim over 20 (including Reissues)

Each independent claim over 3 (including Reissues)

Multiple dependent claims

<u>Total Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>
	<u>-20 or HP =</u>	<u>x</u>	<u>=</u>	<u>Fee (\$)</u>	<u>Fee (\$)</u>

HP = Highest number of total claims paid for, if greater than 20

<u>Indep. Claims</u>	<u>Extra Claims</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>	<u>Small Entity</u>	<u>Fee (\$)</u>
	<u>-3 or HP =</u>	<u>x</u>	<u>=</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>

HP = highest number of independent claims paid for, if greater than 3

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

<u>Total Sheets</u>	<u>Extra Sheets</u>	<u>Number of each additional 50 or fraction thereof</u>	<u>Fee (\$)</u>	<u>Fee Paid (\$)</u>
<u>- 100 =</u>	<u>/ 50 =</u>	<u>(round up to a whole number)</u>	<u>x</u>	<u>=</u>

4. OTHER FEE(S)

Non-English Specification, \$ fee (no small entity discount) _____

Other : 1.20(D) Statutory (Terminal) Disclaimer fee 130.00 130**SUBMITTED BY**

<u>Signature</u>	<u>Joe Liebeschuetz</u>	<u>Registration No.</u> 37,505 <u>(Attorney/Agent)</u>	<u>Telephone</u> 650-326-2400
Name (Print/Type)			Date April 5, 2006

60741641 v1

RECEIVED
CENTRAL FAX CENTER
APR 05 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Lisa C. McConlogue et al.

Application No.: 10/609,143

Filed: June 27, 2003

For: TRANSGENIC ANIMALS HARBORING
APP ALLELE HAVING SWEDISH MUTATION

Confirmation No. 6715

Examiner: Deborah Crouch

Art Unit: 1632

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Elan Pharmaceuticals, Inc. and Eli Lilly and Company (hereinafter "ASSIGNEES") and attorney of record in the above-identified patent application. ASSIGNEES are the assignees of total interest of:

1. Application No. 10/609,143 (the "143 APPLICATION")
2. Application No. 09/838,556 Issued as U.S. Patent No. 6,586,656 (the "656 PATENT")
3. Application No. 09/209,647 Issued as U.S. Patent No. 6,245,964 (the "964 PATENT")
4. Application No. 08/785,943 Issued as U.S. Patent No. 5,850,003 (the "003 PATENT")
5. Application No. 08/148,211 Issued as U.S. Patent No. 5,612,486 (the "486 PATENT")
6. Application No. 08/143,697 Issued as U.S. Patent No. 5,604,102 (the "102 PATENT")

ASSIGNEES are the exclusive owners of the '143 APPLICATION and the '656 PATENT, '964 PATENT, '003 PATENT, '486 PATENT, AND '102 PATENT. ASSIGNEES disclaim the terminal part of any patent granted on the '143 APPLICATION which would extend

beyond the last day of the full statutory term of any of the '656 PATENT, '964 PATENT, '003 PATENT, '486 PATENT, AND '102 PATENT.

Further, ASSIGNEES agree that any patent granted on the '143 APPLICATION shall be enforceable only for and during the period that the legal title to the patent granted on the '143 APPLICATION shall be the same as the legal title to the '656 PATENT, '964 PATENT, '003 PATENT, '486 PATENT, AND '102 PATENT and agrees that this Terminal Disclaimer shall run with any patent granted on the '143 APPLICATION and shall be binding on the grantee or its successors or assigns.

In making the above disclaimer, ASSIGNEES do not disclaim the terminal part of any patent granted on the '143 APPLICATION that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the '656 PATENT, '964 PATENT, '003 PATENT, '486 PATENT, AND '102 PATENT as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.


This disclaimer is directed to patents issuing from the indicated '143 APPLICATION only and is not intended to act as a disclaimer of any part of the statutory term of any patent issuing from a divisional or continuation application that claims priority to either the '143 APPLICATION or to use the term of such a patent issuing from a divisional or continuation application in calculating the term of the present '143 APPLICATION.

The assignment documents evidencing title referred to above have been reviewed by the undersigned, and it is certified that title is in the ASSIGNEES.

DECLARATION

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400/Fax: (650) 326-2422
JOL/ym
60740862 v1